Literature DB >> 7931622

Enzymatic barrier protects brain capillaries from leukotriene C4.

K L Black1, T Baba, W M Pardridge.   

Abstract

Leukotriene C4 (LTC4) increases vascular permeability in systemic, brain tumor, and ischemic brain capillaries, but not in normal brain capillaries. This study examines whether the abundance of gamma-glutamyl transpeptidase (gamma-GTP) in normal brain capillaries might act as an enzymatic barrier to vasoactive leukotrienes in the brain. Blood-brain barrier (BBB) permeability was determined by quantitative autoradiography using 14C-aminoisobutyric acid. Ischemia was produced by occluding the middle cerebral artery. Seventy-two hours after occlusion, gamma-GTP activity in ischemic brain disappeared, and LTC4 (4-micrograms total dose), which was infused into the carotid artery ipsilateral to the occlusion, selectively increased permeability, Ki, approximately twofold within core ischemic tissue and adjacent tissue, compared to vehicle alone in seven brains (15.53 +/- 6.03 vs. 7.29 +/- 3.36, p < 0.05, and 8.76 +/- 4.02 vs. 4.32 +/- 2.65, p < 0.05, respectively). No effect on BBB was seen in nonischemic brain tissue. Twenty-four hours postocclusion, gamma-GTP activity was still present, and LTC4 infusion did not increase permeability within ischemic tissue. However, inhibition of gamma-GTP with acivicin allowed LTC4 to increase permeability even 24 hours after occlusion in ischemic core and adjacent tissue compared to vehicle alone in seven brains (17.21 +/- 16.32 vs. 8.23 +/- 6.58, p < 0.05, and 11.78 +/- 7.96 vs. 4.56 +/- 1.93, p < 0.01, respectively). Acivicin almost completely blocked both the histochemical activity of gamma-GTP in brain capillaries and the metabolism of LTC4 in isolated bovine capillaries. These findings suggest that gamma-GTP may help normal brain capillaries resist the vasoactive effects of LTC4. In contrast, gamma-GTP is lost in injured brain capillaries, which allows LTC4 (in combination with other factors) to increase vascular permeability in ischemic brain and brain tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7931622     DOI: 10.3171/jns.1994.81.5.0745

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  6 in total

Review 1.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

Review 2.  Pharmacological blood-brain barrier modification for selective drug delivery.

Authors:  T F Cloughesy; K L Black
Journal:  J Neurooncol       Date:  1995-11       Impact factor: 4.130

Review 3.  Blood-brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders.

Authors:  Hema Kumari Alajangi; Mandeep Kaur; Akanksha Sharma; Sumedh Rana; Shipali Thakur; Mary Chatterjee; Neha Singla; Pradeep Kumar Jaiswal; Gurpal Singh; Ravi Pratap Barnwal
Journal:  Mol Brain       Date:  2022-06-01       Impact factor: 4.399

4.  Leukotriene E4 selectively increase the delivery of methotrexate to the C6 gliomas in rats.

Authors:  C C Chio; S J Lin; M T Lin
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

5.  Calcium-activated potassium channels mediated blood-brain tumor barrier opening in a rat metastatic brain tumor model.

Authors:  Jinwei Hu; Xiangpeng Yuan; MinHee K Ko; Dali Yin; Manuel R Sacapano; Xiao Wang; Bindu M Konda; Andres Espinoza; Ksenia Prosolovich; John M Ong; Dwain Irvin; Keith L Black
Journal:  Mol Cancer       Date:  2007-03-14       Impact factor: 27.401

6.  LC-MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma.

Authors:  Xiaoyan Liu; Jing Li; Xiaolei Hao; Haidan Sun; Yang Zhang; Liwei Zhang; Lulu Jia; Yongji Tian; Wei Sun
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.